课题基金 / 基金详情

ONCOGENE DIRECTED SYNTHESIS OF CEPHALOSTATIN CANCER DRUG

ONCOGENE DIRECTED SYNTHESIS OF CEPHALOSTATIN CANCER DRUG
癌基因定向合成抗癌药物头孢他汀
批准号:
6370491
负责人:
PHILIP L FUCHS
金额:
$3.16万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-08-09 至 2005-05-31

项目摘要

项目成果

PHILIP L FUCHS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION: (Principal Investigator's Abstract) This proposal has seven medicinal/biological goals: (1) Synthesize up to seven North 1 and South 1 'slightly simplified' hexacyclic steroidal spiroketal subunits. Convert these materials to South--pyrazine--North trisdecacyclic (thirteen rings) pyrazines using our method for unsymmetrical pyrazine synthesis and compare their anticancer activity to cephalostain 1 (1.2nM avg. NCI panel). (2) Study the contribution of the central arene moiety to anticancer activity by testing pairs of unsymmetrical annulated pyridines derived from the best simplified hexacyclic steroidal subunits. (3) Construct and evaluate one member of a designed new class of inter-phylal agents termed the cephalofurthins to evaluate whether the geranyl geranyl moiety is a recognition element. (4) Prepare and test covalent conjugates of the new agent(s) with folic acid to assay for enhanced (targeted) activity for the treatment of the around 40 percent of cancers which over-express (ten to the 4th power) the folate receptor. (5) Use the biological data from testing of the proposed new materials to complete the mapping of the minimum pharmacophore for the cephalostatin class of antieoplastics. (6) Determine the biological mechanism of action of the trisdecacyclic pyrazines; and (7) Prepare 2-5g of the material which best combines high activity with expedient synthesis to provide a set of new biological tools as well as generating enough agent to initiate clinical trials. Synthesis of the seven hexacyclic spiroketals are projected to require 9-16 operations (compared with 29-31 operations in our 'first generation' synthesis). To accomplish the medicinal/biological goals, efficient new chemistry is required. (A) Utilize a vigorous interactive calculational approach to constantly evaluate synthetic approaches and biological testing data. (B) Test a new siloxysulfonium triflate reagent to effect stereospecific allylic oxidation of a vinyl ether. (C) Investigate the resulting ortho-methylthiophenyldimethylsilyl ether for chemospecific ion-pair self-immolative deprotection. (D) Develop a new annulation of unsymmetrical pyridine rings from 3-ketosteroids via an intramolecular aza-Horner reaction. (E) Generation of the Southern hemispheres requires hydroxylation of the unactivated angular methyl group at the steroidal CD ring junction. This will be accomplished by systematic exploration of the potential of a previously unknown stereospecific dyatropic rearrangement of beta-hydroxyketones and beta-hydroxy lactones to accomplish this transformation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ONCOGENE DIRECTED SYNTHESIS OF CEPHALOSTATIN CANCER DRUG
  • 批准号:
    6456877
  • 项目类别:
  • 资助金额:
    $6.49万
  • 财政年份:
    1996
  • 负责人:
    PHILIP L FUCHS
  • 依托单位:
ONCOGENE-DIRECTED SYNTHESIS OF CEPHALOSTATIN CANCER DRUG
  • 批准号:
    2712677
  • 项目类别:
  • 资助金额:
    $20.13万
  • 财政年份:
    1996
  • 负责人:
    PHILIP L FUCHS
  • 依托单位:
ONCOGENE DIRECTED SYNTHESIS OF CEPHALOSTATIN CANCER DRUG
  • 批准号:
    6750698
  • 项目类别:
  • 资助金额:
    $36.84万
  • 财政年份:
    1996
  • 负责人:
    PHILIP L FUCHS
  • 依托单位:
Synthesis & Mechanism of Cephalostatin Anticancer Drugs
  • 批准号:
    7121185
  • 项目类别:
  • 资助金额:
    $29.24万
  • 财政年份:
    1996
  • 负责人:
    PHILIP L FUCHS
  • 依托单位:
海外基金